Project 2: Nucleic Acid Vaccines for the Chemoprevention of Ovarian Cancer Ovarian cancer is highly lethal. Despite the fact that the majority of patients will be diagnosed with advanced stage disease, 60% of those patients will obtain a complete remission with a combination of chemotherapy and surgery. Unfortunately, these remissions will not be sustained and over 70% of patients will relapse and eventually die from progressive ovarian cancer. New treatments and prevention strategies are needed for ovarian cancer. Vaccine directed against ovarian cancer antigens provide therapeutic potential. Recent studies, by several groups including our own, have shown patients with ovarian cancer have an immune response to their tumors and some antigens that are immunogenic in ovarian cancer have been defined. HER-2/neu (HER2) and mutant epidermal growth factor receptor (EGFRvIII) are over-expressed growth factor receptors present in 30 and 75% of ovarian cancers respectively. Both these proteins elicit immune responses in patients whose tumors express the proteins. Furthermore, preliminary studies in animal and/or human models suggest that antibodies directed against HER2 and EGFRvIII may mediate an anti- tumor response. Some patients against the tumor antigen. If these antibody responses could be boosted, via immunization, to potentially therapeutic molecular immunology and the definition of antigen recognition by T cells has allowed the identification of co-stimulatory molecules and soluble factors such as cytokines' which influence the immune environment. Nucleic acid vaccines (DNA vaccines) which are engineered to encoded both the appropriate co-stimulation and tumor antigen for the generation of growth factor specific antibody responses may allow significant levels of endogenous tumor specific antibodies to be generated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083636-03S1
Application #
6502463
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-30
Project End
2002-09-29
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998

Showing the most recent 10 out of 187 publications